Moderna Inc (MRNA)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$241.50
Buy
$241.92
$15.19 (+6.69%)
Prices updated at 21 Oct 2026, 00:59 EDT
| Prices minimum 15 mins delay
Prices in USD
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna ha ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2025 | 54.84 |
| 2024 | 54.24 |
| 2023 | 30.52 |
| 2022 | 71.31 |
| 2021 | 85.24 |
| 2020 | 97.08 |
| 2019 | 100.00 |
| 2018 | 100.00 |
| 2017 | - |
| 2016 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2026 | 40.40 |
| 2025 | 5.15 |
| 2024 | 3.13 |
| 2023 | 4.25 |
| 2022 | 3.67 |
| 2021 | 9.74 |
| 2020 | 686.37 |
| 2019 | 92.51 |
| 2018 | 23.12 |
Price/Forward earnings (YTD)
-
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2025 | -21.31 |
| 2024 | -21.87 |
| 2023 | -21.29 |
| 2022 | 33.10 |
| 2021 | 76.25 |
| 2020 | -16.74 |
| 2019 | -28.94 |
| 2018 | -26.38 |
| 2017 | -21.57 |
| 2016 | -16.25 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2025 | 1.43 |
| 2024 | 1.30 |
| 2023 | 1.33 |
| 2022 | 1.35 |
| 2021 | 1.74 |
| 2020 | 2.86 |
| 2019 | 1.35 |
| 2018 | 1.28 |
| 2017 | - |
| 2016 | - |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
